Abstract | BACKGROUND: METHODS: This multicentre open trial randomized 80 patients with AMI complicated by cardiogenic shock expected to undergo primary PCI into group A (routine upfront-pre-procedural- abciximab bolus followed by 12-h abciximab infusion) and group B (standard therapy). The study primary objective was 30-day combined outcome (death/reinfarction/ stroke/new severe renal failure). RESULTS: PCI was technically successful in 90% (A) versus 87.5% (B) patients. Abciximab was used in 100% (A) versus 35% (B). The primary endpoint occurred in 17 group A patients (42.5%) and 11 group B patients (27.5%, P = 0.24). Ejection fraction among survivors after 30 days was 44 ± 11% (A) versus 41 ± 12% (B, P = 0.205). Major bleeding occurred in 17.5% (A) versus 7.5% (B, P = 0.310). No differences (A versus B) were found in TIMI-flow and MBG after PCI. CONCLUSIONS: This study did not show any benefit from routine pre-procedural abciximab when compared with a selective abciximab use during the intervention in patients with cardiogenic shock undergoing primary PCI. However, small sample size of the trial preclude any definitive conclusion, a larger prospective, randomized, multicentered trial is needed.
|
Authors | Petr Tousek, Richard Rokyta, Jitka Tesarova, Radek Pudil, Jan Belohlavek, Josef Stasek, Filip Rohac, Petr Widimsky |
Journal | Acute cardiac care
(Acute Card Care)
Vol. 13
Issue 3
Pg. 116-22
(Sep 2011)
ISSN: 1748-295X [Electronic] England |
PMID | 21526919
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Abciximab
|
Topics |
- Abciximab
- Aged
- Angioplasty, Balloon, Coronary
(methods)
- Antibodies, Monoclonal
(administration & dosage)
- Czech Republic
- Female
- Humans
- Immunoglobulin Fab Fragments
(administration & dosage)
- Male
- Middle Aged
- Myocardial Infarction
(complications, drug therapy, mortality, pathology)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Prospective Studies
- Shock, Cardiogenic
(complications, drug therapy, mortality, pathology)
- Stroke Volume
- Survival Analysis
- Treatment Outcome
|